Obesity and high C-peptide levels predict worse outcome in men with prostate cancer

2009 ◽  
Vol 6 (2) ◽  
pp. 61-61
Keyword(s):  
Prostate Cancer ◽  
C Peptide

The association between plasma C-peptide concentration and the risk of prostate cancer

2018 ◽  
Vol 27 (5) ◽  
pp. 461-467 ◽  
Author(s):  
Grace Y. Kiyabu ◽  
Norie Sawada ◽  
Motoki Iwasaki ◽  
Taiki Yamaji ◽  
Taichi Shimazu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
C Peptide ◽  
Peptide Concentration

On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 153-153 ◽  
Author(s):  
J. P. Dean ◽  
R. B. Montgomery ◽  
J. Wan ◽  
P. Cohen ◽  
K. Haugk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Clinical Laboratory ◽  
Clinical Stage ◽  
Human Monoclonal Antibody ◽  
Combined Treatment ◽  
Androgen Deprivation ◽  
Serum Samples ◽  
C Peptide ◽  
Target Activity

153 Background: IMC-A12 (cixutumumab) is a fully human monoclonal antibody which targets the insulin-like growth factor receptor 1. Preclinical data suggests that the combination of androgen deprivation and IMC-A12 is much more effective than either treatment alone. This clinical trial tests the effectiveness of the combined treatment in a neoadjuvant fashion before radical prostatectomy. We have assayed serum samples from the first 18 patients to identify signs of on-target activity in this setting. Methods: Eligible men with high risk localized prostate cancer are defined by one of the following: Gleason score ≥ 8, PSA ≥ 20, Clinical Stage T2c-T3, or a risk for relapse exceeding 50% as defined by the Kattan nomogram. Men are treated for 3 months with goserelin, bicalutamide, and biweekly IMC-A12 infusions (10 mg/kg). The primary objective of the trial is to determine the rate of pathological complete response with an accrual goal of 28 men. Using samples from the first 18 patients on study, serum protein markers were assayed by ELISA and serum PSA and glucose levels were determined by clinical laboratory analysis. Results: Significant increases in c-peptide (1.7-fold, p<0.01), IGF-I (4.1-fold, p<0.01), IGF-II (1.32-fold, p<0.001), IGFBP-3 (1.9-fold, p<0.01), growth hormone (8-fold, p<0.01) were noted after initiation of ADT+IMC-A12, compared to pre-treatment levels. Non-significant increases of insulin (1.9-fold), IGFBP-1 (2-fold), and glucose (1.24-fold) levels were seen. Stratification of patients by nadir PSA levels correlated with residual tumor volume, likelihood of positive surgical margins and likelihood of lymph node metastases. Interestingly, patients with lower nadir PSA levels had smaller increases in c-peptide (50%, p<0.01), insulin (66%, p<0.02) and blood sugar (21%, P<0.01) compared to the patients with higher nadir PSA levels. Conclusions: Combined with ADT in the neoadjuvant setting, IMC-A12 effectively targets the IGF-1R axis in prostate cancer patients. Metabolic differences between patients may alter the efficacy of IMC-A12 in this setting. [Table: see text]

scholarly journals Prediagnostic C-Peptide and Risk of Prostate Cancer: Table 1.

2007 ◽  
Vol 16 (10) ◽  
pp. 2164-2165 ◽  
Author(s):  
Marilyn J. Borugian ◽  
John J. Spinelli ◽  
Zheng Sun ◽  
Laurence N. Kolonel ◽  
Ingrid Oakley-Girvan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
C Peptide

scholarly journals Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial

The Prostate ◽  
2009 ◽  
Vol 69 (12) ◽  
pp. 1303-1311 ◽  
Author(s):  
Jeannette M. Schenk ◽  
Alan R. Kristal ◽  
Marian L. Neuhouser ◽  
Catherine M. Tangen ◽  
Emily White ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Prevention ◽  
Prostatic Hyperplasia ◽  
Prevention Trial ◽  
Serum Adiponectin ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
C Peptide ◽  
Prostate Cancer Prevention ◽  
Prostate Cancer Prevention Trial

scholarly journals No Association of Plasma Levels of Adiponectin and c-peptide with Risk of Aggressive Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort

2014 ◽  
Vol 23 (5) ◽  
pp. 890-892 ◽  
Author(s):  
Victoria L. Stevens ◽  
Eric J. Jacobs ◽  
Juzhong Sun ◽  
Susan M. Gapstur
Keyword(s):  
Prostate Cancer ◽  
Cancer Prevention ◽  
Plasma Levels ◽  
Prevention Study ◽  
C Peptide ◽  
Aggressive Prostate Cancer

scholarly journals Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study

2014 ◽  
Vol 25 (5) ◽  
pp. 625-632 ◽  
Author(s):  
Gabriel Y. Lai ◽  
Edward L. Giovannucci ◽  
Michael N. Pollak ◽  
Sarah B. Peskoe ◽  
Meir J. Stampfer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
Health Professionals ◽  
Prostate Cancer Incidence ◽  
C Peptide ◽  
Follow Up Study

Inflammatory and insulinemic dietary patterns: Influence on circulating biomarkers and prostate cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) cohort.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17561-e17561
Author(s):  
Desmond Aroke ◽  
Edmund Folefac ◽  
Qi Jin ◽  
Ni Shi ◽  
Steven K. Clinton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Dietary Patterns ◽  
Cox Regression ◽  
Prostate Cancer Risk ◽  
Low Grade ◽  
High Grade ◽  
C Peptide ◽  
Prostate Carcinogenesis ◽  
Hazard Ratios

e17561 Background: Prostate cancer (PCa) is common in countries with affluent dietary patterns and represents a heterogeneous collection of subtypes with varying behavior. Reductionist strategies focusing on individual nutrients or foods have not clearly defined risk factors. We have developed mechanisms-based dietary patterns focusing upon inflammation and chronic insulin hypersecretion, processes that are hypothesized to impact prostate carcinogenesis. Methods: First, we examined associations of the empirical dietary index for hyperinsulinemia (EDIH) and empirical dietary inflammatory pattern (EDIP) scores with circulating concentrations of relevant biomarkers, to assess the validity of these two dietary patterns. Secondly, we investigated associations of the EDIH and EDIP with risk of PCa (total, low-grade, high-grade, advanced and lethal). EDIH and EDIP dietary scores calculated from food frequency questionnaire data for 3,517 men and women who provided a blood sample at enrollment, were used to validate dietary patterns against known relevant biomarkers. A separate sample of 49,317 men was used to evaluate the associations of EDIH and EDIP with prostate cancer risk. We used multivariable-adjusted linear regression to compute the percent change and 95% confidence intervals (95%CI) in biomarker concentrations, and Cox regression to estimate hazard ratios (HR) and 95%CI for PCa risk; in dietary score quintiles, using the lowest quintile as reference. Results: Compared to the lowest quintile, participants in the highest EDIH quintile (most hyperinsulinemic diets) had significantly higher concentrations of C-peptide, insulin, CRP, and TNF-R2 and lower adiponectin. Those consuming the most pro-inflammatory diets (EDIP) had significantly higher concentrations of IL-6, TNF-R2, C-peptide and insulin with lower adiponectin. Men classified in EDIH quintile 5 compared to 1, were also at higher total PCa risk: HR, 1.11; 95%CI, 1.01, 1.23; P-trend = 0.03, especially high-grade cancer: HR, 1.18; 95%CI, 1.02, 1.37; P-trend = 0.06; whereas the EDIP was not associated with risk. Conclusions: EDIH and EDIP predicted concentrations of biomarkers relevant to the insulinemic and inflammatory potential of diet in PLCO. EDIH predicted future PCa risk and may suggest a dietary pattern for PCa prevention.

scholarly journals Serum C-peptide concentration and prostate cancer

Medicine ◽  
2018 ◽  
Vol 97 (31) ◽  
pp. e11771
Author(s):  
Zhen-Lang Guo ◽  
Xiang-Tao Weng ◽  
Franky-Leung Chan ◽  
Lei-Liang Gong ◽  
Song-Tao Xiang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
C Peptide ◽  
Peptide Concentration

scholarly journals Association between C-Peptide Concentration and Prostate Cancer Incidence in the CLUE II Cohort Study

2010 ◽  
Vol 3 (10) ◽  
pp. 1334-1341 ◽  
Author(s):  
Gabriel Y. Lai ◽  
Kathy J. Helzlsouer ◽  
Sandra L. Clipp ◽  
Nader Rifai ◽  
Elizabeth A. Platz
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Cancer Incidence ◽  
Prostate Cancer Incidence ◽  
C Peptide ◽  
Peptide Concentration
Sign in / Sign up

Export Citation Format

Share Document